Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and -C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report

about

Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and -C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report

Item

http://www.wikidata.org/entity/Q58761509

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Effective treatment of pulmona ...... ination therapy: a case report

@en

Effective treatment of pulmona ...... ination therapy: a case report

@nl

type

Item

label

Effective treatment of pulmona ...... ination therapy: a case report

@en

Effective treatment of pulmona ...... ination therapy: a case report

@nl

prefLabel

Effective treatment of pulmona ...... ination therapy: a case report

@en

Effective treatment of pulmona ...... ination therapy: a case report

@nl

P1476

Effective treatment of pulmona ...... ination therapy: a case report

@en

P2093

Gang Wang

http://www.w3.org/2001/XMLSchema#string

Guangzhi Wang

http://www.w3.org/2001/XMLSchema#string

Jing Zhao

http://www.w3.org/2001/XMLSchema#string

Jinyan Lv

http://www.w3.org/2001/XMLSchema#string

Ming Zou

http://www.w3.org/2001/XMLSchema#string

Yingmin Han

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.

P304

5545-5550

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.2147/OTT.S170358

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30233215

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

bevacizumab

P932

6134962

http://www.w3.org/2001/XMLSchema#string